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Abstract 
Background: This study aims to determine the synergistic effects of the chemotherapeutic drug melphalan and the 
phytoconstituents extracted from Pinus kesiya Royle ex Gordon (Simaosong) in human cancer cells.
Methods: P. kesiya twigs extracted from 50 % ethanol–water were evaluated alone (6–500 µg/mL) and in combina-
tion with melphalan (0.75–15 µg/mL). The cytotoxic effects of single extract or extract and melphalan combination 
were examined by a neutral red assay to investigate their antiproliferative and apoptosis induction effects in the U937 
and HepG2 cell lines. Nuclei morphological change and DNA fragmentation were examined by DNA nuclei staining 
with 4´6-diamidino-2-phenylindole (DAPI) and agarose gel electrophoresis, respectively. The chemical constituents of 
the P. kesiya extract were assessed using gas chromatography–mass spectrometry (GC–MS) analysis. The synergistic 
effects of different IC50 ratios of the P. kesiya extract and melphalan combination were analyzed in each cancer cell 
line. The dose reduction index (DRI) was calculated to determine the extent of concentration reduction in the combi-
nation treatment compared with the concentration of each single treatment.
Results: The IC50 ratios for melphalan to P. kesiya extract that caused 75 % antiproliferation could be reduced after 
combination. This response was greater in the U937 cells than in the HepG2 cells (all P < 0.001). Melphalan and P. 
kesiya extract had a similar effect on apoptosis induction both singly and in combination. P. kesiya extract synergized 
the antiproliferation and apoptosis induction effects of melphalan.
Conclusions: Combining the P. kesiya extract with melphalan reduced toxicity while retaining the therapeutic effi-
cacy of melphalan.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Specific and selective apoptosis induction in targeted 
chemotherapy is limited due to multidrug resistance and 
intolerably severe side effects [1, 2]. Synergistic combina-
tions of two or more agents could overcome the toxicity 
and side effects associated with the high doses of chem-
otherapeutic drugs in monotherapy [3]. Several herbal 
plant extracts are rich sources of bioactive constitu-
ents that inhibit, reverse, or retard tumorigenesis [3, 4]. 
Additionally, some research on herbal synergistic action 
indicates that the whole herb produces a better effect than 
any single isolated active ingredient [5, 6].
The rosin of Pinus kesiya Royle ex Gordon (Simao-
song) contains szemaoenin (diterpenoid) isopimaric acid, 
abiet-13(14)-en-8,12-epoxy-18-oic acid, abiet-8,11,13-
trien-15-hydroxy-18-oic acid, pimarol, isopimarol, abiet-
8,11,13-trien-18-oic acid, and 15-hydroxyabietic acid 
[7]. The main compounds found in P. kesiya turpentine 
are α- and β-pinene [8]. The needle oil is rich in α- and 
β-pinene, citronellol, bornyl acetate, β-phellandrene, 
camphene, and β-caryophyllene [9]. The needles of 
P. kesiya contain dichlorobenzene isomer, 1,4-cineol, 
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α-terpinene, o-cimene and imonene enantiomers [10, 
11], and monoterpenes [12].
P. kesiya is used to relieve flatulence, stomachache, and 
cough in complementary and alternative medicine [13]. 
The 50 % ethanol–water crude extract of the woody twigs 
of P. kesiya has an apoptotic-induction effect on both the 
human hepatocellular carcinoma HepG2 and the human 
leukemic U937 cell lines because of its cytotoxicity [14, 
15]. Many studies indicate that this effect arises from 
the whole crude extract with its lower activity of isolated 
individual compounds [3–6]. The synergistic effect of the 
whole extract of P. kesiya plus the chemotherapeutic drug 
melphalan is of interest as it may expand the use of this 
herbal plant. Melphalan is an alkylating anticancer drug, 
leading to DNA cross-linking, DNA damage, and finally 
apoptosis of cancer cells [16]; however, melphalan resist-
ance and highly toxic side effects in other tissues limit 
its use [17, 18]. We hypothesized that plant extracts that 
exhibited an anticancer activity in  vitro might enhance 
the antiproliferative activity of melphalan, which would 
permit the use of a lower dosage and reduced side effects. 
This study aims to determine the synergistic effects of P. 




P. kesiya woody twigs were collected and taxonomically 
authenticated by Assistant Professor Thaweesak Thi-
timetharoach. The species of samples were determined 
using the Flora of Thailand [19] and the Thai Forest Bul-
letin [20]. The voucher (TT-OC-SK-910) was deposited 
at the Herbal Herbarium, Faculty of Pharmaceutical 
Sciences, Khon Kaen University, Khon Kaen Province, 
Thailand. The 50  % ethanol–water extract of P. kesiya 
twig was prepared as previously reported [14, 15]. Dried 
plants were cut and macerated with 50 % ethanol–water 
(1  kg:6  L) for 7  days with occasional manual shaking. 
The solvent was filtered, distilled by a rotary evaporator 
(RV 8 V, IKA, Germany) below 40°C, and freeze-dried to 
obtain the crude extract. The percent yield of the 50  % 
ethanol–water extract of P. kesiya was 4.3 %. Stock solu-
tion of P. kesiya extract was freshly prepared in dimethyl 
sulfoxide (DMSO) to make 100  mg/mL stock solution 
and further diluted with culture media to create a work-
ing solution (10 to 500 µg/mL).
Gas chromatography–mass spectrometry (GC–MS) analysis
GC–MS analysis was performed as described by Weera-
preeyakul et al. [21] on an Agilent 6890 N gas chroma-
tograph (Agilent Technologies, China) coupled to an 
Agilent 5973  N mass selective detector (Agilent Tech-
nologies, USA) to determine the extract composition for 
further standardization. Capillary GC analysis was per-
formed using a DB-5 ms (3 m ×  0.25 mm id, 0.25 µm) 
capillary column from Agilent Technologies (J&W Sci-
entific, USA) with helium as the carrier gas. The column 
initially flowed at 80 °C for 6 min at a rate of 2 mL/min 
and an average velocity of 52 cm/s. The temperature was 
raised to 280  °C (at a rate of 5  °C/min) for 24 min. The 
total runtime was 70 min. The injector temperature was 
maintained at 250 °C and the injection volume was set at 
2.0  µL in the splitless mode. The interface temperature 
was held at 280 °C. Mass spectra were scanned from m/z 
50.0 to m/z 500.0 at a rate of 1.5 scans/s with a thresh-
old of 150. The electron impact ionization energy was 
70  eV. The chemical components of the crude extracts 
were identified from the chromatograms and mass spec-
tra using the Wiley 7 N.l database (Agilent Technologies, 
USA).
Cell culture
The human leukemic (U937) cell line was cultured 
in RPMI 1640. The human hepatocellular carcinoma 
(HepG2) cell line and normal African green mon-
key kidney epithelial (Vero) cell line were cultured in 
DMEM (GIBCO, Invitrogen Corporation, USA). Both 
media were supplemented with 10 % fetal bovine serum 
(GIBCO, Invitrogen Corporation), 100 units/mL peni-
cillin and 100  µg/mL streptomycin (GIBCO, Invitro-
gen Corporation). The cells were cultured at 37  °C in a 
humidified atmosphere containing 5 % CO2.
Antiproliferative effect
The antiproliferative activity of the P. kesiya extract in 
the leukemia (U937), hepatocellular carcinoma (HepG2), 
and normal (Vero) cell lines was assessed by neutral red 
assay [14, 15]. Briefly, 100 µL of U937 cells at a density of 
5 × 105 cells/mL and 100 µL of HepG2 or Vero cells at a 
density of 3 × 105 cells/mL were independently seeded in 
96-wells plates and incubated for 24 h. After cell growth, 
cells were treated with various concentrations (10 to 
500  µg/mL) of the P. kesiya crude extract or melphalan 
(purity 95  %, Sigma–Aldrich Chemie GmbH, Germany) 
dissolved in DMSO (United States Biological, USA). 
The maximum final concentration of the compound was 
500 µg/mL to maintain 1 % v/v DMSO with a cytotoxic-
ity <10 % compared with the untreated cells. After treated 
cells were exposed to the test compound for 24  h, cells 
were stained directly with a final concentration of 50 µg/
mL neutral red dye (Sigma Chemicals Co., USA) and incu-
bated for another 2 h. The neutral red stained viable cells 
were dissolved by 0.33  % hydrogen chloride in isopro-
panol and detected using a colorimetric-based method. 
The absorbance was measured at 520 and 650 nm (refer-
ence wavelength) by a spectromicroplate reader (TECAN, 
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Grödig, Austria). A plot of percentage cytotoxicity vs. test 
compound concentration was used to calculate the IC50.
Apoptosis induction effect
Nuclei morphological study by 4´6‑diamidino‑2‑phenylindole 
(DAPI) staining assay
The apoptosis effect of the plant crude extracts was 
primarily determined by fluorescent dye staining and 
DAPI to identify the condensation and fragmentation of 
nuclear DNA [14, 15]. Briefly, the cancer cells (HepG2 
or U937) were treated with various concentrations of 
the test compounds (6  to  500  µg/mL of P. kesiya and 
0.75  to  15  µg/mL of melphalan) for 24  h, after which 
the culture medium was removed and the cells were 
washed with fresh medium. Cells were then fixed by cold 
methanol. DAPI dye (Sigma–Aldrich Chemie GmbH, 
Germany) was then added to stain the nuclei DNA for 
1  h. The excess dye was removed and 1X PBS (pH 7.4; 
10 mM) was added to glycerin (at a 1:1 ratio). The DAPI 
staining assay was performed in triplicate in independ-
ent experiments. An inverted fluorescence microscope 
(Nikon eclipse 80i, Kanagawa, Japan) was used to record 
images of the DAPI staining. The average percentage of 
apoptotic cells was calculated from three independent 
wells with 10 eye views per well under the inverted fluo-
rescence microscopy at a magnitude of 40×.
Analysis of DNA fragmentation
DNA fragmentation was analyzed [14, 15]. Briefly, after 
cancer cells were treated with various concentrations of P. 
kesiya extracts (60, 150, 300, 450, and 500 µg/mL) and mel-
phalan (15 µg/mL) for 24 h, they were collected and washed 
with fresh medium. Then, the cell suspension was trans-
ferred to microcentrifuge tubes and centrifuged (Daihan 
Scientific, Seoul, Korea) at 300×g for 5 min to collect the 
cell pellet. The DNA in the cell pellet was extracted using a 
FlexiGene DNA kit (QIAGEN GmbH, Germany) then 2 µg 
of the DNA was analyzed using electrophoresis on 2 % aga-
rose gels (Bio-Rad, USA) containing 0.1 mg/mL ethidium 
bromide (AppliChem, USA). DNA was mixed with loading 
dye (SibEnzyme Ltd., Russia) and the gel electrophoresed in 
0.5X Tris–Borate-EDTA buffer (pH 8.3; 40 mMTris base, 
45  mM boric acid, 1  mM EDTA; Sigma–Aldrich Chemie 
GmbH, Germany) at 250  V for 1  min and 20  V for 4  h. 
After electrophoresis, the DNA fragments were analyzed 
by In Genius L gel documentation (Syngene, USA).
Enhancement of anticancer effect of P. kesiya extract 
in vitro
The enhanced chemosensitivity of melphalan combined 
with P. kesiya on the U937 and HepG2 cell lines was 
determined as per Chou and Talalay [22]. The antipro-
liferation assay on the melphalan and P. kesiya extract 
combination treatment against the HepG2 cancer cell 
line after 24 h was performed using the same method as 
for melphalan or P. kesiya extract alone. The cells were 
treated with the P. kesiya extract and melphalan was 
added subsequently. Different concentrations of the P. 
kesiya extract and melphalan combination treatment 
were used (Table  1). Briefly, the melphalan concentra-
tion was fixed at 1 ×  IC50 and the P. kesiya concentra-
tion was varied at 0.02, 0.05, 0.1, 0.2, 0.5, 1, 1.5, and 
2 ×  IC50 in the U937 and HepG2 cell lines. In another 
series, the P. kesiya extract concentration was fixed at 
1 × IC50 and the melphalan concentration was varied at 
0.05, 0.1, 0.2, 0.5, 1, 1.5, and 2 × IC50 in both cancer cell 
lines. The maximum concentration that could be used 
in the experiment to maintain the percentage DMSO at 
less than 1 % v/v was 500 µg/mL, instead of a 2 ×  IC50 
concentration of P. kesiya (600  µg/mL), the concentra-
tion used in this study was only 500 µg/mL. After 24 h 
exposure, the percentage of antiproliferation for each 
treatment was calculated.
The combined effects were analyzed to determine 
whether the enhanced growth inhibitory effect was 
antagonistic, additive, or synergistic. The combination 
index (CI) was calculated (adapted from the multiple-
drug effect analysis based on the median effect princi-
ple and the isobologram technique developed by Chou 
[22] and Eid et  al. [23]). The CI took into account both 
the potency and shape of the dose–effect curve, which is 
given by Eq. (1):
CI > 1, = 1, and <1 correspond to synergism, addition, 
and antagonism, respectively. The denominators (Dx)1 
and (Dx)2 are the doses of a single treatment of the first 
and second compound designated as 1 and 2, respec-
tively. Additionally, (D)1 and (D)2 are the doses of the 
compounds 1 and 2 in the combination treatment that 
exhibited x % antiproliferation.
The calculated dose reduction index (DRI) was used 
to determine the extent of dose reduction in the combi-
nation treatment compared with the dose of each single 
treatment. For the combination effect, DRI was defined 













The same antiproliferation experiment was performed 
on the normal Vero cells to provide a comparison to 
determine the cytotoxic effect of combining the com-
pounds against the normal cells. The synergistic apop-
totic effects of the combination of P. kesiya extract and 
melphalan were evaluated against the U937 and HepG2 
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Statistical analysis
Experiments were performed in triplicate and the results 
were expressed as a mean  ±  standard deviation   from 
three independent experiments. Statistical analysis was 
performed by IBM SPSS Statistics 17.0 (SPSS Inc., Chi-
cago, IL, USA). A two-way analysis of variance (ANOVA) 
test followed by Fisher’s least significant difference test 
for multiple comparisons of independent experiments 
were used to determine the effective enhancement of the 
inhibition growth by P. kesiya and melphalan in various 
cell lines. The significance level was set at P < 0.05. Sta-
tistical differences of percentage apoptotic cells between 
the P. kesiya treated group and the positive control group 
were compared by one-way ANOVA followed by Tukey’s 
honest significant difference test with a significance level 
of P < 0.05.
Results
Antiproliferative effects of P. kesiya extract and melphalan 
singly versus in combination on U937 and HepG2 cell lines
The antiproliferative effects of P. kesiya extract and 
melphalan singly or in combination were investigated 
in U937 and HepG2 cell lines. The IC50 values of P. kes-
iya in U937 and HepG2 were 299.0  ±  5.2  µg/mL and 
52.0 ± 5.8 µg/mL, respectively. The IC50 values of mel-
phalan in U937 and HepG2 were 15.0 ± 1.0 µg/mL and 
37.7 ± 9.8 µg/mL, respectively. Both melphalan and P. 
kesiya extract caused significantly greater antiprolifera-
tion than was observed in untreated cancer cells (con-
trol). P. kesiya extract exerted potent antiproliferation 
in the HepG2 cells at an IC50 value of 52.0  ±  5.8  µg/
mL. P. kesiya extract had a stronger selectivity against 
the two cancer cell lines than melphalan. A significant 
enhanced antiproliferative effect occurred with the 
combination when treating human U937 and HepG2 
cell lines (Table 2). A two-way ANOVA was conducted 
that examined the effect of IC50 ratio and cell types on 
percentage antiproliferation. There was a statistically 
significant interaction between the effects of IC50 ratio 
and cell types on percentage antiproliferation, F(26, 
84) =  42.654, P < 0.001. A two-way ANOVA detected 
significant differences in the antiproliferative activ-
ity of the various IC50 ratios (all P < 0.001) and among 
the various cell lines (P  <  0.001). Significantly higher 
antiproliferative activities were observed at P. kesiya 
to melphalan concentration ratios of 0.2:1, 0.5:1, 1:1, 
1.5:1, 2:1, 1:0.2, 1:0.5, 1:1.5, and 1:2 compared with 
normal Vero cells (P  <  0.001). When the concentra-
tion of melphalan was constant, an enhanced antipro-
liferative effect was observed at P. kesiya to melphalan 
concentration ratios of 0.05:1 and 0.5:1 in the U937 
and HepG2 cell lines, respectively. Alternatively, when 
P. kesiya was constant, the enhanced antiproliferative 
effect was observed at melphalan to P. kesiya concen-
tration ratios of 0.1:1 and 0.2:1 in the U937 and HepG2 
cell lines, respectively.
Melphalan alone exhibited strong antiproliferation in 
normal Vero cells at an IC50 value of 59.9 ± 3.2 µg/mL, 
while P. kesiya extract alone was inactive in normal Vero 
cells. When treating the Vero cells, the antiprolifera-
tion of the combination treatment was  <25  % when the 
concentration of melphalan was constant (Table 2). The 
result showed an antagonistic effect of P. kesiya extract 
on the antiproliferation of melphalan in Vero cells. In 
the presence of a 1  ×  IC50 concentration of P. kesiya, 
the concentration of melphalan used could be as high 
as 2 × IC50, producing only 9.5 ± 1.9 % antiproliferation 
against Vero cells.
Synergistic effect of melphalan and P. kesiya extract 
combination analyzed in U937 leukemic and HepG2 
hepatocellular carcinoma cell lines
The CIs of the combined effect of P. kesiya and melpha-
lan in the U937 and HepG2 cell lines at IC75 and IC90 
values are presented in Table  3 and Fig.  1. Our results 
indicated that the combination of P. kesiya and melpha-
lan exhibited high synergistic effects in U937 and HepG2 
Table 2 Antiproliferation of  P. kesiya extract and  melpha-
lan combination in U937, HepG2, and Vero cell lines
Two-way ANOVA detected significant antiproliferative activity differences 
among various IC50 ratios (P < 0.001) and among various cell lines (P < 0.001). A 
significant two-way interaction was observed between IC50 ratio and various cell 
lines (P < 0.001)
Nd not determined
a IC50 value of melphalan in Vero cells equals 59.9 ± 3.2 µg/mL
b Inactive when IC50 of P. kesiya in Vero cells was >500 µg/mL
IC50 Ratio % Antiproliferation
P. kesiya Melphalan U937 HepG2 Vero
0 1 50 50 50a
1 0 50 50 Inactiveb
1 1 100 ± 7.0 95.7 ± 12.2 6.8 ± 1.9
0.02 1 46.0 ± 5.7 Nd Nd
0.05 1 59.8 ± 5.3 Nd Nd
0.1 1 76.6 ± 13.5 Nd 1.0 ± 3.5
0.2 1 79.3 ± 3.7 43.7 ± 2.9 4.0 ± 6.1
0.5 1 100 ± 7.0 82.1 ± 4.9 7.3 ± 1.9
1.5 1 100 ± 2.2 93.4 ± 1.6 16.4 ± 4.7
2 1 100 ± 11.3 100 ± 3.1 24.7 ± 9.1
1 0.05 46.8 ± 9.5 34.2 ± 4.4 Nd
1 0.1 51.8 ± 5.5 46.0 ± 9.1 Nd
1 0.2 73.0 ± 4.2 60.7 ± 16.4 0 ± 3.3
1 0.5 76.4 ± 3.6 65.1 ± 9.1 1.8 ± 1.2
1 1.5 100 ± 2.0 100 ± 10.5 8.6 ± 1.4
1 2 100 ± 3.4 100 ± 4.9 9.5 ± 1.9
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Table 3 Dose reduction index (DRI) and combination index (CI)
DRI and CI of the combination treatment of P. kesiya/melphalan in U937 or in HepG2 cells at the concentrations that produced 90 and 75 % antiproliferation
% Antiproliferation Cell lines Combination treatment DRI CI
P. kesiya Melphalan
90 % (IC90) U937 Fixed [P. kesiya] = IC50 2.3 7.8 0.56
Fixed [melphalan] = IC50 6.5 5.5 0.33
HepG2 Fixed [P. kesiya] = IC50 2.0 3.6 0.79
Fixed [melphalan] = IC50 2.4 3.2 0.74
75 % (IC75) U937 Fixed [P. kesiya] = IC50 1.8 8.7 0.66
Fixed [melphalan] = IC50 9.1 3.8 0.37
HepG2 Fixed [P. kesiya] = IC50 1.6 3.8 0.90
Fixed [melphalan] = IC50 2.7 2.4 0.79
Fig. 1 Isobolograms of the plot between combination index (CI) and fa in U937 (black symbol) and HepG2 (white symbol). fa = fraction affected by 
D (i.e., percentage antiproliferation/100). Isobolograms of the combination of compounds when P. kesiya was fixed (a, c; square), and when melpha-
lan was fixed (b, d; circle) in each cancer cell lines
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cells at concentrations producing 75 and 90  % antipro-
liferation (IC75 and IC90). As observed from the higher 
synergistic effect (low CI value), the combination ther-
apy was more effective on the U937 cells than on the 
HepG2 cells.
Extent of dose reduction in the combination treatment 
compared with single doses of each treatment
Table 3 shows the decreased concentration of melpha-
lan or P. kesiya extract in the combination therapy to 
produce 90 and 75  % antiproliferation in U937 cells 
and HepG2 cells. The concentration of melphalan 
(when combined with a fixed concentration of P. kes-
iya extract) necessary to inhibit cancer growth by 90 % 
(IC90) represents a 7.8- and 3.6-fold decrease in U937 
and HepG2 cells, respectively. By comparison, the con-
centration of P. kesiya extract (when combined with a 
fixed concentration of melphalan) needed for the IC90 
represents a 6.5- and 2.4-fold decrease in U937 and 
HepG2 cells, respectively. A similar DRI trend (i.e., a 
greater melphalan dose reduction) for U937 cells com-
pared with HepG2 cells was observed at 75  % anti-
proliferation. Dose reduction also depended on the 
type of cancer cells: 90 and 75  % cell death occurred 
when the P. kesiya extract concentration was fixed. 
The doses for melphalan per dose of P. kesiya extract 
could be reduced in the U937 cells (10.55:300 = 0.04:1 
and 6.6:300  =  0.02:1) more than in the HepG2 cells 
(33.7:55.0  =  0.61:1 and 23.7:55.0  =  0.43:1). The syn-
ergistic effect appears to be greater for the melphalan 
because a greater potential dose reduction could be 
achieved; thus, melphalan concentrations could be sig-
nificantly reduced.
Apoptotic induction effect of single treatments and of P. 
kesiya extract and melphalan combination treatment
Apoptosis induction by P. kesiya extract and melpha-
lan when used singly or in combination was evaluated 
in HepG2 and U937 cell lines using a method based on 
the DAPI staining assay (Table  4) and DNA fragmenta-
tion assays (Fig. 2). In the control group, the nuclei were 
roundish and homogeneously stained by DAPI; in con-
trast, the apoptotic nuclei in the treated U937 and HepG2 
cells were irregularly shaped, small, detached, and had 
apoptotic bodies. At a 1 ×  IC50 concentration, P. kesiya 
extract induced 42.5  ±  4.8 and 39.7  ±  2.6  % apoptosis 
in the U937 and HepG2 cells, respectively; melphalan 
induced 43.1 ± 16.3 and 53.0 ± 6.1 % apoptosis, respec-
tively. The combination therapy of P. kesiya extract and 
melphalan was significantly more effective in inducing 
apoptosis against U937 and HepG2 cells.
DNA fragmentation was determined according to 
whether the synergistic apoptosis induction in both 
cancer cells occurred toward the late stage of apoptosis, 
as previously observed for single therapy [15]. The com-
bined treatment of P. kesiya with melphalan resulted in 
DNA laddering in both the HepG2 and U937 cells com-
pared with the control cells (Fig. 2).
GC–MS analysis of P. kesiya extract
GC–MS analysis of P. kesiya extract was performed 
to obtain its characteristic fingerprint (Table  5). The 
GC peaks obtained were used for further chemi-
cal constituent identification and revealed several 
compounds:podocarpa-8,11,13-trien-15-oic acid, neo-
pine, rosin acid, pimaric acid, oleic acid, pyrocatecol, and 
vanillin (Table 5).
Discussion
To our knowledge, this is the first report of a synergistic 
effect of P. kesiya extract on melphalan anticancer activ-
ity via the apoptosis induction mechanism in  vitro. The 
U937 cells were only sensitive to melphalan, based on the 
lower IC50 value; however, the HepG2 cells were sensitive 
to both P. kesiya extract and melphalan. A wide chemo-
preventive index was observed in the combination treat-
ment, probably because the cytotoxic effect was lower in 
the normal Vero cells. P. kesiya extract’s potent antipro-
liferation effect in the HepG2 cell line and high selective 
antiproliferation effect in both cancer cell lines requires 
further investigation.
Table 4 Effects of  P. kesiya and  melphalan on  apoptosis 
induction in U937 and HepG2 cells
One-way ANOVA of percentage apoptotic cells compared with single treatment 
by melphalan at 1 × IC50 in cancer cells
a Significant difference (P < 0.001)
b Non-significant difference (P ≥ 0.001)
IC50 ratio % Apoptotic cells
IC50 of P. kesiya IC50 of Melphalan U937 HepG2
0 1 43.1 ± 16.3 53.0 ± 6.1
1 0 42.5 ± 4.8b 39.7 ± 2.6a
1 1 100a 100a
0.1 1 77.0 ± 1.9a 66.7 ± 3.1a
0.2 1 100a 74.9 ± 12.3a
0.5 1 100a 92.8 ± 1.3a
1.5 1 100a 98.3 ± 3.0a
2 1 100a 100a
1 0.05 38.6 ± 6.1a 62.4 ± 3.2a
1 0.1 48.4 ± 3.8a 87.9 ± 3.3a
1 0.2 61.3 ± 3.3a 90.3 ± 6.0a
1 0.5 100a 100a
1 1.5 100a 100a
1 2 100a 100a
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Drug and herb combinations could significantly 
decrease the toxicity and chemoresistance of drugs and 
increase their efficacy [24, 25] i.e., increasing the efficacy 
of the therapeutic effect; decreasing the dosage to avoid 
toxicity; reducing the development of drug resistance; 
and providing selective synergism against a target (or 
efficacy synergism) vs. host (or toxicity antagonism). The 
ability of herbal extracts to enhance anticancer activity 
might also arise from the potentiation of pharmacoki-
netics, wherein one ingredient enhanced the therapeutic 
effect of another (active ingredient or drug) by modulat-
ing its pharmacokinetic properties (i.e., absorption, dis-
tribution, metabolism, and/or excretion) [24, 25]. The 
administration of multiple therapeutic agents is often 
associated with additional toxicities, which can be life 
threatening; however, a combination treatment with 
a non-toxic herbal extract like P. kesiya might provide 
superior benefits.
Previous work indicated that, in addition to the com-
pounds identified here in P. kesiya extract (Table  5), 
gallic acid, chlorogenic acid, caffeic acid, vanillin, and 
coumaric acid in the 50  % ethanol–water extract of P. 
kesiya exhibited an anticancer effect [14]. The main 
compounds found in various parts of Pinaceae were ter-
penes, such as α- and β-pinene [26]. Rosin is composed 
of a complex mixture of different compounds, including 
resin acids such as abietic acid, plicatic acid, and pima-
ric acid. Resin acids might be derived from terpenes 
Fig. 2 DNA fragments after combination treatment of P. kesiya (Pk) extract with melphalan in HepG2 (a) and U937 (b) cell lines
Table 5 Identified compounds and  their relative distribu-
tion in P. kesiya
GC–MS data of the 50 % ethanol–water crude extract of P. kesiya
Retention time (min) % of Total area Assigned compounds




29.551 1.55 Palmitic acid
32.878 4.49 Oleic acid
35.650 4.16 Benzoyl isocyanate
36.096 4.77 Pimaric acid
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through partial oxidation and undergo isomerization in 
the presence of strong acids or with heat [27]. Hence, 
terpenes such as α- and β-pinene might undergo ther-
mal conversion into resin acids under the GC–MS 
condition studied. One previous study reported that 
α-pinene expressed both apoptosis induction and anti-
metastatic activity against melanoma cells [26]. A previ-
ous work has also shown that citronellol—found in the 
family Pinaceae—inhibited an efflux P-gp protein at an 
IC50 value of 504 µM [28].
Conclusions
Combining the P. kesiya extract with melphalan reduced 
toxicity while retaining the therapeutic efficacy (reduced 
approximately 4–9 fold) of melphalan.
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